6
12
↑6
↓12
—0
Evidence suggests MDMA maydecreaseStress.
24 studies (18 claims)
Moderate consensus
Typical effective dose 72.5 (46.25–98.75) mgacross 2 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| MDMA-assisted psychotherapy | Decreases - holds immense promise for addressing | post-traumatic stress disorder (PTSD) | Human | female subgroups | Not specified | Women and MDMA: particularities of gender and sex.cited 2× |
| MDMA-assisted psychotherapy | Decreases - has shown potential as an effective treatment | post-traumatic stress disorder (PTSD) | Animal | — | Microinjected into the medial prefrontal cortex (mPFC); exact dosage not specified. | Examining the Role of Oxytocinergic Signaling and Neuroinflammatory Markers in the Therapeutic Effects of MDMA in a Rat Model for PTSD.cited 3× |
| MDMA-assisted psychotherapy (MDMA-AP) | Decreases - is a proposed treatment | posttraumatic stress disorder (PTSD) | Human | adults | Not specified | MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.cited 7× |
| MDMA-assisted psychotherapy (MDMA-AP) | Decreases - shows promise in the treatment of | posttraumatic stress disorder (PTSD) | Human | individuals with chronic PTSD | Not specified in the abstract. | Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.cited 9× |
| MDMA-assisted psychotherapy | Decreases - not meeting posttraumatic stress disorder criteria | posttraumatic stress disorder criteria | Human | people with chronic posttraumatic stress disorder | 40 mg, 100 mg, and 125 mg administered during eight-hour psychotherapy sessions (two sessions for active doses, with additional open-label sessions). | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.cited 123× |
| MDMA-assisted psychotherapy | Decreases - remained lower than baseline | Posttraumatic stress disorder symptoms | Human | people with chronic posttraumatic stress disorder | 40 mg, 100 mg, and 125 mg administered during eight-hour psychotherapy sessions (two sessions for active doses, with additional open-label sessions). | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.cited 123× |
| MDMA-assisted psychotherapy | Decreases - reduces | posttraumatic stress disorder symptoms | Human | people with chronic posttraumatic stress disorder | 40 mg, 100 mg, and 125 mg administered during eight-hour psychotherapy sessions (two sessions for active doses, with additional open-label sessions). | 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.cited 123× |
| MDMA-assisted psychotherapy | No effect - investigated the potential role | treatment for post-traumatic stress disorder | Human | — | Not specified | Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective.cited 7× |
| MDMA | Decreases - reported positive outcomes | depression, anxiety, posttraumatic stress disorder, and drug or alcohol use disorders | Human | — | Not specified | Licit use of illicit drugs for treating depression: the pill and the process. |
| MDMA (3,4-methylenedioxymethamphetamine, ecstasy) | Increases - mediated | oxidative/nitrosative stress | Animal | — | Not specified | Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage.cited 46× |
| MDMA | No effect - promising outcomes for the therapeutic utility | post-traumatic stress disorder | HumanAnimalMolecular | — | Not specified | The external gate of the human and Drosophila serotonin transporters requires a basic/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux.cited 3× |
| MDMA | Decreases - highly promising preliminary data have been produced | post-traumatic stress disorder (PTSD) | Human | — | Not specified | Psychedelic drugs-a new era in psychiatry? .cited 53× |
| MDMA | Decreases - effectively alleviate symptoms | post-traumatic stress disorder | Human | patients | Not specified | Psychoactive substances for the treatment of neuropsychiatric disorders.cited 2× |
| MDMA | No effect - designated as breakthrough therapy | posttraumatic stress disorder (PTSD) | Human | — | Not available. | Psychedelics and Psychedelic-Assisted Psychotherapy.cited 315× |
| MDMA | No effect - has risen in prominence as an agent to treat | posttraumatic stress disorder (PTSD) | Human | PTSD patients | Not mentioned | Why MDMA therapy for alcohol use disorder? And why now?cited 18× |
| MDMA | Decreases - demonstrated to be useful to treat | post-traumatic stress disorders | Human | — | Not specified | Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.cited 114× |
| MDMA | Decreases - stress-relieved | stress | Human | patients with chronic complex post-traumatic stress disorder (c-PTSD), dissociative, and other post-traumatic disorders | Not specified | Using a MDMA- and LSD-Group Therapy Model in Clinical Practice in Switzerland and Highlighting the Treatment of Trauma-Related Disorders.cited 25× |
| MDMA | Increases - increases | thermal stress | Human | — | Not specified | Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research.cited 112× |
| MDMA | No effect - has shown promise as an adjunct to psychotherapy | treatment of post-traumatic stress disorder | Human | — | 0.75 mg/kg and 1.5 mg/kg MDMA, 20 mg methamphetamine. | MDMA enhances positive affective responses to social feedback.cited 5× |
| Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA | Increases - has shown promise | conditions including depression and post-traumatic stress disorder | Human | — | Not mentioned | Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.cited 1× |
| MDMA-assisted therapy | No effect - demonstrated the most promise | posttraumatic stress disorder (PTSD) | Human | — | Not specified | Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine-Assisted Therapy for Posttraumatic Stress Disorder: A Review of the Evidence, Neurobiological Plausibility, and Clinical Significance.cited 8× |
| MDMA-assisted therapy | No effect - anticipated FDA approval | posttraumatic stress disorder | Human | — | Not mentioned | The need for establishing best practices and gold standards in psychedelic medicine.cited 12× |
| MDMA-assisted therapy (MDMA-AT) | Increases - positive results | treatment of post-traumatic stress disorder (PTSD) | Human | patients with PTSD | Not specified | Expert opinions on implementation of MDMA-assisted therapy in Europe: critical appraisal towards training, clinical practice, and regulation. |